Brexit Could Be a Boost For GSK


Britain’s decision to leave the European Union will come with a host of repercussions for regulatory agencies such as the EMA and public healthcare institutions such as the NHS. However, some multinational pharmaceutical firms may benefit from the UK’s decision to leave. GlaxoSmithKline is based in the UK but earns most of its money offshore, which means a drop in the pound could stand to benefit them financially.

Read the source article at Financial Review

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>